{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T00:44:25Z","timestamp":1720313065948},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.euroneuro.2008.04.006","type":"journal-article","created":{"date-parts":[[2008,5,30]],"date-time":"2008-05-30T06:05:46Z","timestamp":1212127546000},"page":"S146-S152","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S3","title":["Do we need another atypical antipsychotic?"],"prefix":"10.1016","volume":"18","author":[{"given":"Siegfried","family":"Kasper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2008.04.006_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis \u2014 incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0028-1094312","article-title":"Ergebnisse eines Doppelblindversuches von HF 1854 (8-Chlor-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)1,4)diazepin) im Vergleich zu Levomepromazin","volume":"4","author":"Angst","year":"1971","journal-title":"Pharmakopsychiatrie"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.yic.0000177020.26311.a7","article-title":"A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia","volume":"21","author":"Azorin","year":"2006","journal-title":"Int. Clin. Psychopharmcol."},{"issue":"3","key":"10.1016\/j.euroneuro.2008.04.006_bib6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/schbul\/11.3.440","article-title":"Treatment of negative symptoms","volume":"11","author":"Carpenter","year":"1985","journal-title":"Schizophr. Bull."},{"issue":"suppl 99","key":"10.1016\/j.euroneuro.2008.04.006_bib7","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/BF00442559","article-title":"Clozapine: neuroleptic-induced EPS and tardive dyskinesia","volume":"53","author":"Casey","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib8","series-title":"Prescribing Information","author":"Clozaril\u00ae (clozapine)","year":"2005"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib9","series-title":"Summary of Product Characteristics","author":"Clozaril\u00ae (clozapine)","year":"2005"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib10","first-page":"61","article-title":"Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia","volume":"34","author":"Daniel","year":"1998","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ddr.430310305","article-title":"Effect of sertindole on raised mesolimbic dopaminergic activity in the rat","volume":"31","author":"Domeney","year":"1994","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.300.1.64","article-title":"Electrophysiological characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsdaogenic potential despite QT prolongation","volume":"300","author":"Eckardt","year":"2002","journal-title":"J. Phamacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2007-990291","article-title":"Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol","volume":"40","author":"Gallhofer","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"B.M.J."},{"issue":"suppl 3","key":"10.1016\/j.euroneuro.2008.04.006_bib15","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/00004850-199803003-00011","article-title":"A review of the safety and tolerability of sertindole","volume":"13","author":"Hale","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/13651500050518406","article-title":"Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial","volume":"4","author":"Hale","year":"2000","journal-title":"Int. J. Psych. Clin. Pract."},{"issue":"suppl 1","key":"10.1016\/j.euroneuro.2008.04.006_bib17","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1080\/13651500215969","article-title":"Sertindole: cardiac electrophysiological profile","volume":"6","author":"Haverkamp","year":"2002","journal-title":"Int. J. Psych. Clin. Pract."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib19","first-page":"327","article-title":"Does clozapine cause tardive dyskinesia?","volume":"54","author":"Kane","year":"1993","journal-title":"J. Clin. Psychiatry"},{"issue":"Supplement 3","key":"10.1016\/j.euroneuro.2008.04.006_bib50","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1097\/00004850-199803003-00010","article-title":"Sertindole: a review of clinical efficacy","volume":"13","author":"Kane","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"suppl. 4","key":"10.1016\/j.euroneuro.2008.04.006_bib20","first-page":"S4","article-title":"Negative symptoms and sertindole","volume":"6","author":"Kasper","year":"1996","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"suppl. 1","key":"10.1016\/j.euroneuro.2008.04.006_bib21","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1080\/13651500215967","article-title":"Sertindole: safety and tolerability profile","author":"Kasper","year":"2002","journal-title":"Int. J. Psych. Clin. Pract."},{"issue":"4","key":"10.1016\/j.euroneuro.2008.04.006_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s002130050579","article-title":"Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol \u2014 a 123I-IBZM SPECT study","volume":"136","author":"Kasper","year":"1998","journal-title":"Psychopharmacology"},{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2008.04.006_bib23","first-page":"S59","article-title":"A review of the benefit-risk profile of sertindole","volume":"2","author":"Kasper","year":"1998","journal-title":"Int. J. Psych. Clin. Pract."},{"issue":"suppl. 2","key":"10.1016\/j.euroneuro.2008.04.006_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00014165","article-title":"Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia","volume":"249","author":"Kasper","year":"1999","journal-title":"Eur. Arch. Psychiatry. Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib25","series-title":"Advances in Preclinical and Clinical Psychiatry","first-page":"47","article-title":"The efficacy of sertindole on the positive and negative symptoms of schizophrenia","author":"Kasper","year":"2000"},{"issue":"1","key":"10.1016\/j.euroneuro.2008.04.006_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib27","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","article-title":"Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory met-analysis of randomised, controlled trials","volume":"160","author":"Leucht","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.euroneuro.2008.04.006_bib28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1017\/S1461145705005250","article-title":"QTc interval prolongation and antipsychotic drug treatments: focus on sertindole","volume":"8","author":"Lindstr\u00f6m","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.04.006_bib30","series-title":"Sertindole is Superior to Haloperidol in Cognitive Performance in Patients with Schizophrenia: A Comparative Study. Poster presented at ECNP. Prague, 20\u201324 September","author":"Lis","year":"2003"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib31","series-title":"Schizophrenia","article-title":"Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia","author":"Mattay","year":"2003"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib32","author":"Medicines and Healthcare Regulatory Agency"},{"issue":"suppl 3","key":"10.1016\/j.euroneuro.2008.04.006_bib33","first-page":"15","article-title":"Suicide in schizophrenia: Risk factors and clozapine treatment","volume":"59","author":"Meltzer","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.euroneuro.2008.04.006_bib34","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1080\/13651500210340","article-title":"Higher cardiovascular mortality with sertindole in ADROIT: A signal not confirmed","volume":"6","author":"Moore","year":"2002","journal-title":"Int. J. Psych. Clin. Pract."},{"issue":"suppl 2","key":"10.1016\/j.euroneuro.2008.04.006_bib35","first-page":"41","article-title":"A review of the efficacy, tolerability and safety of sertindole in clinical trials","volume":"18","author":"Perquin","year":"2004","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib37","first-page":"33","article-title":"Ziprasidone finally completes FDA's obstacle course","volume":"36","author":"Rosack","year":"2001","journal-title":"Psychiatr. News"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib38","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomised controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ddr.430220306","article-title":"Neurochemical and in vivo pharmacological profile of Sertindole, a limbic-selective neuroleptic compound","volume":"22","author":"Sanchez","year":"1991","journal-title":"Drug Dev. Res."},{"issue":"suppl 2","key":"10.1016\/j.euroneuro.2008.04.006_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00023210-200418002-00004","article-title":"Case histories illustrating the utility of sertindole in clinical practice","volume":"18","author":"Schuck","year":"2004","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib41","series-title":"Summary of Product Characteristics","author":"Serdolect\u00ae (sertindole)","year":"2005"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/syn.890100105","article-title":"Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment","volume":"10","author":"Skarsfeldt","year":"1992","journal-title":"Synapse"},{"issue":"9","key":"10.1016\/j.euroneuro.2008.04.006_bib45","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4088\/JCP.v66n0907","article-title":"Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study","volume":"66","author":"Tenback","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF02245618","article-title":"A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia","volume":"124","author":"van Kammen","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2008.04.006_bib48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ajp.154.6.782","article-title":"Controlled, dose\u2013response study of sertindole and haloperidol in the treatment of schizophrenia","volume":"154","author":"Zimbroff","year":"1997","journal-title":"Am. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X08000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X08000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T00:23:45Z","timestamp":1545956625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X08000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":43,"alternative-id":["S0924977X08000874"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2008.04.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}